# Belite Bio, Inc: Form 20-F for the period ended Dec 31, 2022

- Company: [Belite Bio, Inc](/companies/blte.md) (CIK 1889109)
- Form: 20-F
- Filed: 2023-03-31
- Accepted by EDGAR: Mar 31, 2023, 16:02 ET
- Period: 2022-12-31
- Accession: 0001104659-23-040145
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1889109/000110465923040145/blte-20221231x20f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1889109/000110465923040145/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 12 months, 2022-01-01 to 2022-12-31 | $8.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months, 2022-01-01 to 2022-12-31 | −$12.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2022-01-01 to 2022-12-31 | $16.0k | us-gaap:InterestExpense |
| Net income | 12 months, 2022-01-01 to 2022-12-31 | −$12.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2022-01-01 to 2022-12-31 | −$0.63 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2022-01-01 to 2022-12-31 | −$0.63 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2022-01-01 to 2022-12-31 | 19,976,596 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2022-01-01 to 2022-12-31 | −$11.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2022-01-01 to 2022-12-31 | $394.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2022-12-31 | $42.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-12-31 | $42.8m | us-gaap:AssetsCurrent |
| Total assets | at 2022-12-31 | $44.3m | us-gaap:Assets |
| Current liabilities | at 2022-12-31 | $2.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-12-31 | $2.8m | us-gaap:Liabilities |
| Shareholders' equity | at 2022-12-31 | $41.5m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2022-12-31 | 24,898,908 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1889109/000110465923040145/blte-20221231x20f.htm

Filed Mar 31, 2023.
Source: SEC EDGAR, the filing index for accession 0001104659-23-040145. Last ingested by Listed: Oct 30, 2026, 21:01 ET. No prices; not investment advice.